We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
39 hedge funds and large institutions have $3.49M invested in ImmunoCellular Therapeutics, Ltd. in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
5% more funds holding
Funds holding: 37 → 39 (+2)
16% less call options, than puts
Call options by funds: $789K | Put options by funds: $938K
60% less capital invested
Capital invested by funds: $8.67M → $3.49M (-$5.18M)
Holders
39
Holders Change
+2
Holders Change %
+5.41%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
15
Reduced
9
Closed
6
Calls
$789K
Puts
$938K
Net Calls
-$149K
Net Calls Change
+$1.65M
Top Buyers
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$329K |
| 2 |
D.E. Shaw & Co
New York
|
+$286K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
+$284K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$273K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$254K |
